Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
Xilio Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Xilio Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$60.60M. For fiscal 2025 it was -$4.99M. The highest annual figure on record is -$4.99M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.99M | – |
| FY2024 | Dec 31, 2024 | -$18.38M | – |
| FY2023 | Dec 31, 2023 | -$68.62M | – |
| FY2022 | Dec 31, 2022 | -$75.72M | – |
| FY2021 | Dec 31, 2021 | -$80.75M | – |
| FY2020 | Dec 31, 2020 | -$36.09M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.34M | -177.1% |
| Q4 FY2025 | Dec 31, 2025 | -$2.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.48M | -172.6% |
| Q1 FY2025 | Mar 31, 2025 | $28.98M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.67M | – |
| Q2 FY2024 | Jun 30, 2024 | $19.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.50M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.43M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.16M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.71M | – |
See a number that looks wrong?